Alcatel-Lucent Rises From The Grave
Last weak, Goldman Sachs said Alcatal-Lucent revenue was in "free fall" due to management’s inability to properly manage the merger of the two telecom equiment markers. The ALU stock was at $15.28 in January,…
Last weak, Goldman Sachs said Alcatal-Lucent revenue was in "free fall" due to management’s inability to properly manage the merger of the two telecom equiment markers. The ALU stock was at $15.28 in January,…
A new, very large test, shows that bare-metal stents barely work in patients with chronic chest pain who have their heart disease managed with medicine. Boston Scientific needs stent use to continue to rise…
Life does not get any easier for Pfizer (PFE). Forget generics. Now other drug firms are ganging up on them. Merck (MRK) and Schering-Plough are going to offer drug that combines their cholestoral drug…
ACS cut to Hold at Jefferies.BEC cut to Mkt Perform at Piper Jaffray.BID raised to Strong Buy at JMP Securities.CVTX cut to Sell at Deutsche Bank.DELL raised to Buy at Goldman Sachs.HNAB cut to…
Markets in Europe were narrowly mixed at 6.35 AM New York time. The FTSE was up.2% to 6,350. Barclays was down 1.8% to 744. BP was up 1.1% to 547.5 BT was down .1%…
There are several big banks that might like to have Citi’s (C) consumer bank network in the US and abroad. HSBC (HBC) comes to mind. So do BNP Paribus and UBS. The investment banking…
Citigoup (C) is about to announce that it will cut 15,000 jobs and take a $1 billion charge. For a company that watched expenses rise $7.4 billion last year, it is a drop in…
Late word is that Saudi Basic, the big petrochemical company may buy GE Plastics fro $12 billion. Private equity firms looked at buying the unit, but there were concerns that the US government saw…
According to Reuters, UPS is launching a service that will allow customers to re-route packages while they are in transit. Reuters writes that Intel (INTC) has made a final decision to build at $2.5…
Dendreon(DNDN-NASDAQ) is going to be one of "THE TOP ISSUES" this week. The company will have and FDA review panel on Thursday, and you should just expect that if you are an active trader…
Markets in Asian were slightly higher. The Nikkei rose .2% to 17,522. Bridgestone was up down 1.6% to 2440. Canon was down .9% to 6520. Fuji Film was down .2% to 4880. Hitachi was…
Yesterday the finger pointing over the Subprime headache took a turn for the worst when U.S. Senators accused the Federal Reserve and its former chairman, Alan Greenspan, of a "pattern of neglect" that fostered…
By Yaser Anwar, CSC of Equity Investment Ideas This week I’d like to talk about: 1) Europe ‘s: Economics (mixed signals), Earnings (utilities look strong), Bonds (steepening curve), 2) Insider Buying (L-3 worth noting) and…
From AAO Weblog Finally, a “normal” sort of SAB 108 adjustment… normal, at least, in the context of what you’d expect. Home healthcare provider Apria Healthcare Group went the cumulative-adjustment group in their 10-K…
The following list represents the top ten medical stocks ranked according to Earnings Per Share and Relative Strength by Investor’s Business Daily (3/24/07) scores out of 100 (last week’s rank, change in score): 1(1)…
From World Beta Investors can’t seem to get their fill from the private equity fountain. . . The magazine cover indicator(see below for description) would be screaming to get out of private equity right…
By Vitaliy Katsenelson, CFA As you look at the high-flying Russian stock market, you may feel like you want some of it. But before you dive into Russia consider this: as it is, Russia…
From Investment Intelligencer Bullish market seers often point to today’s big profits when arguing that there are great things to come. Because today’s big profits are due to today’s record-high profit margins, however, they…
Submitted by CrossProfit Actually it is a trifle more complicated than that. Private equity at first was a way for the wealthy to invest differently than the common man. The ideas was to find…
I have received comments on Dendreon (DNDN-NASDAQ) for this week that are both positive and negative on how well its Sipuleucel-T (Provenge) is thought of ahead of the FDA panel review this week. This…